Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR | P11473 | 16/20 | 0.70 |
| ▸ | AR | P10275 | 5/20 | 0.58 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1778744 | 0.97 | VDR (0.72) | VDRARHDAC3HDAC6 | |
| SCHEMBL2963746 | 0.90 | VDR (0.79) | VDRARHDAC3HDAC6 | |
| SCHEMBL1779520 | 0.89 | VDR (0.73) | VDRARHDAC3HDAC6 | |
| SCHEMBL1778007 | 0.86 | VDR (0.75) | VDRARHDAC3HDAC6 | |
| SCHEMBL2969641 | 0.85 | VDR (0.79) | VDRARHDAC3HDAC6 | |
| SCHEMBL2082721 | 0.85 | VDR (0.60) | VDRARHDAC3 | |
| SCHEMBL1779694 | 0.85 | VDR (0.73) | VDRARHDAC3HDAC6 | |
| SCHEMBL3850276 | 0.84 | VDR (0.59) | VDRAR | |
| SCHEMBL2083884 | 0.84 | VDR (0.59) | VDRARHDAC3 | |
| SCHEMBL3850804 | 0.84 | VDR (0.59) | VDRAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943795-B2 | Vitamin D receptor modulators | ELI LILLY AND COMPANY (US) | 2011-05-17 | — | — | US | disclosed |
| US-7943795-B2 | Vitamin D receptor modulators | ELI LILLY AND COMPANY (US) | 2011-05-17 | — | — | US | disclosed |
| US-20090234001-A1 | VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY | 2009-09-17 | — | — | US | disclosed |
| US-20090234001-A1 | VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY | 2009-09-17 | — | — | US | disclosed |
| EP-1836151-B1 | VITAMIN D RECEPTOR MODULATORS | LILLY CO ELI (US) | 2009-04-01 | — | — | EP | disclosed |
| EP-1836151-B1 | VITAMIN D RECEPTOR MODULATORS | LILLY CO ELI (US) | 2009-04-01 | — | — | EP | disclosed |
| EP-1836151-A2 | VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006069153-A2 | VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090234001-A1 | VITAMIN D RECEPTOR MODULATORS | VDR, CYP2R1, CYP24A1 | VDR 1/4885AR 95/4885HDAC3 809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.